Mickle Travis C
Known title: President & CEOCIK: 0001638365
Mickle Travis C's purchase track record
Mickle Travis C has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/25/2022 | ZVRA | $57K | +39.4% | +6.6% | +1.2% |
| 11/18/2021 | ZVRA | $19K | -32.0% | -38.4% | -17.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▲ Buy | Open Market | 2,000 | $9K | 5/25/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,000 | $4K | 5/25/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 10,000 | $44K | 5/25/2022 | View on chart |
| ZVRA | ▲ Buy | Open Market | 2,250 | $19K | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.